Macrogenics profit margin MGNX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.
- Net margin, 12 months
- −8.7%
- Operating margin, 12 months
- −24.3%
- Net margin on a year earlier
- +15.5 pts
- Peer median
- 11.6%
Over the twelve months to Jun 30, 2026, Macrogenics kept −8.7% of its revenue as net profit, with an operating margin of −24.3%.
The median for 10 large drugmakers of a similar size is 11.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −55.6% | −59.1% | 84.6% |
| FY2024 | −44.7% | −73.7% | 91.8% |
| FY2023 | −15.4% | n/a | 86.0% |
| FY2022 | −78.8% | −79.9% | n/a |
| FY2021 | n/a | n/a | 96.6% |
| FY2020 | n/a | n/a | 100.0% |
| FY2019 | n/a | n/a | n/a |
| FY2018 | n/a | n/a | n/a |
| FY2017 | −12.4% | −14.0% | n/a |
| FY2016 | −63.7% | −65.3% | n/a |
| FY2015 | −20.0% | −20.0% | n/a |
| FY2014 | −80.2% | −80.2% | n/a |
| FY2013 | −0.4% | 0.6% | n/a |
| FY2012 | 13.1% | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −8.7% | +15.5 pts | −24.3% | |
| Q1 FY26 | −49.6% | −13.4 pts | −49.5% | |
| Q4 FY25 | −55.6% | −11.0 pts | −59.1% | |
| Q3 FY25 | −67.6% | +1.5 pts | n/a | |
| Q2 FY25 | −24.2% | n/a | −56.3% | |
| Q1 FY25 | −36.2% | +17.4 pts | −64.6% | |
| Q4 FY24 | −44.7% | −29.2 pts | −73.7% | |
| Q3 FY24 | −69.1% | −110.2 pts | −75.8% | |
| Q2 FY24 | n/a | n/a | n/a | |
| Q1 FY24 | −53.6% | +1.6 pts | n/a | |
| Q4 FY23 | −15.4% | +63.4 pts | n/a | |
| Q3 FY23 | 41.1% | n/a | −88.3% |
Against its peers
Companies in Drug Manufacturers - General nearest Macrogenics' size, closest first, today.
| Company | Profit margin |
|---|---|
| MGNXMacrogenics | −8.7% |
| NATRNatures Sunshine Products | 3.7% |
| LFVNLifevantage | 2.8% |
| SPROSpero Therapeutics | 15.7% |
| ATNMActinium Pharmaceuticals | n/m |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| Peer median | 11.6% |
Where Macrogenics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Macrogenics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.